- Home
- Mutual Funds
- Tata Mutual Fund
- Tata India Pharma & Healthcare Fund Direct-idcw
Fund Overview of Tata India Pharma & Healthcare Fund Direct-idcw
-
₹1,455.2 CrAUM
-
₹37.87NAV
-
0.97%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of Tata India Pharma & Healthcare Fund Direct-idcw
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 15.37% | NA | 6.12% |
| 6 Months | 11.53% | NA | 12.92% |
| 1 Year | 10.50% | 10.50% | 6.04% |
| 2 Years | 24.99% | 11.80% | 24.93% |
| 3 Years | 86.03% | 22.99% | 25.71% |
| 5 Years | 101.83% | 15.08% | 19.91% |
| 7 Years | 318.17% | 22.68% | NA |
| 10 Years | 302.94% | 14.95% | 12.78% |
Dividends are declared by the fund house based on the income generated from the underlying assets. While many mutual funds distribute dividends annually, the payout frequency ultimately depends on the fund house’s decision
Asset Allocation
equities
97.42%other assets or cash equivalents
2.58%Tata India Pharma & Healthcare Fund Direct-idcw is one Equity mutual fund offered by Tata Mutual Fund. Launched on 28 Dec 2015, the fund aims Long Term Capital Appreciation. Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India. It manages assets worth ₹1,455.2 crore as on Tue Jun 30, 2026. The expense ratio stands at 0.97%. Fund Manager Manager EducationAbout Tata India Pharma & Healthcare Fund Direct-idcw
The portfolio allocation consists of 97.42% in equities, 2.58% in other assets or cash equivalents.Managed by Rajat Srivastava, it has delivered a return of 10.50% in the last year, a total return since inception of 13.81%.
The latest dividend was declared on 08 May 2026 at 12.00% of face value.
Based on individual goals investors may evaluate which sip is best during the overall investment planning.
Key Metrics of Tata India Pharma & Healthcare Fund Direct-idcw
-
Standard Deviation16.76%
-
Mean21.99%
-
Sharpe Ratio0.97%
-
Alpha-1.57%
-
Beta0.99%
-
Sortino Ratio1.49%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Plan-growth  |
₹4,998 | 5.79% | 18.51% | 16.45% | 24.91% | 17.56% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,998 | 5.79% | 18.51% | 16.45% | 24.91% | 17.56% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,625 | 5.28% | 16.15% | 9.76% | 26.26% | 16.85% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,625 | 5.28% | 16.15% | 9.76% | 26.26% | 16.85% |
| SBI Healthcare Opportunities Fund-growth |
₹4,998 | 5.71% | 18.22% | 15.28% | 23.62% | 16.33% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,998 | 5.71% | 18.22% | 15.28% | 23.62% | 16.33% |
| DSP Healthcare Fund Direct-growth |
₹3,514 | 6.45% | 19.94% | 13.84% | 23.67% | 16.27% |
| DSP Healthcare Fund Direct-idcw |
₹3,514 | 6.45% | 19.94% | 13.84% | 23.67% | 16.27% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,253 | 5.91% | 17.51% | 15.87% | 25.12% | 15.92% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,253 | 5.91% | 17.51% | 15.87% | 25.12% | 15.92% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from Tata Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
Tata India Pharma & Healthcare Fund Regular-growth
|
₹1,455 | 5.61% | 14.97% | 10.76% | 8.92% | 21.20% |
|
Tata India Pharma & Healthcare Fund Direct-growth
|
₹1,455 | 5.73% | 15.37% | 11.53% | 10.50% | 22.99% |
|
Tata India Pharma & Healthcare Fund Regular-idcw
|
₹1,455 | 5.61% | 14.97% | 10.76% | 8.92% | 21.20% |
|
Tata Nifty Midsmall Healthcare Index Fund Regular-growth
|
₹182 | 6.06% | 18.29% | 16.23% | 13.39% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Direct-growth
|
₹182 | 6.12% | 18.47% | 16.57% | 14.08% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Regular-idcw
|
₹182 | 6.06% | 18.29% | 16.23% | 13.39% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Direct-idcw
|
₹182 | 6.12% | 18.47% | 16.57% | 14.08% | - |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹9,044 | ₹564.60 | 20.30% | 12.55% | 15.12% |
| Nippon India Pharma Fund Direct-growth |
₹9,044 | ₹634.41 | 21.38% | 13.57% | 16.14% |
| Nippon India Pharma Fund-idcw |
₹9,044 | ₹121.92 | 20.30% | 12.55% | 15.12% |
| Nippon India Pharma Fund Direct-idcw |
₹9,044 | ₹173.62 | 21.38% | 13.57% | 16.14% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,625 | ₹43.71 | 25.22% | 15.84% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,625 | ₹47.47 | 26.26% | 16.85% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,625 | ₹25.50 | 25.22% | 15.84% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,625 | ₹28.67 | 26.26% | 16.85% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,998 | ₹499.11 | 23.62% | 16.33% | 13.49% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,998 | ₹577.24 | 24.91% | 17.56% | 14.74% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.92% | ₹146.17 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.87% | ₹130.76 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.38% | ₹130.11 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.03% | ₹130.01 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.03% | ₹130.01 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.59% | ₹127.09 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.59% | ₹127.09 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.34% | ₹127.07 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.66% | ₹125.61 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 8.51% | ₹123.89 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 8.51% | ₹123.89 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 8.51% | ₹123.89 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 8.51% | ₹123.89 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.31% | ₹115.36 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 7.75% | ₹103.73 Cr |
| Sun Pharmaceutical Industries Ltd | Healthcare | 7.88% | ₹103.31 Cr |
| Cipla Ltd | Healthcare | 6.62% | ₹88.60 Cr |
| Max Healthcare Institute Ltd | Healthcare | 6.78% | ₹88.23 Cr |
| Max Healthcare Institute Ltd | Healthcare | 5.68% | ₹82.71 Cr |
| Max Healthcare Institute Ltd | Healthcare | 5.68% | ₹82.71 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹577.24 | 24.91% | 17.56% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹401.05 | 24.91% | 17.56% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹47.47 | 26.26% | 16.85% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹28.67 | 26.26% | 16.85% | - |
| SBI Healthcare Opportunities Fund-growth |
₹499.11 | 23.62% | 16.33% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹314.41 | 23.62% | 16.33% | - |
| DSP Healthcare Fund Direct-growth |
₹49.56 | 23.67% | 16.27% | - |
| DSP Healthcare Fund Direct-idcw |
₹28.66 | 23.67% | 16.27% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹50.57 | 25.12% | 15.92% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹30.46 | 25.12% | 15.92% | - |
growth is based on 5Y returns of the funds
Frequently Asked Questions
Tata India Pharma & Healthcare Fund Direct-idcw
What is the current AUM of Tata India Pharma & Healthcare Fund Direct-idcw?
As of Tue Jun 30, 2026, Tata India Pharma & Healthcare Fund Direct-idcw manages assets worth ₹1,455.2 crore
How has Tata India Pharma & Healthcare Fund Direct-idcw performed recently?
- 3 Months: 15.37%
- 6 Months: 11.53%
What is the long-term performance of Tata India Pharma & Healthcare Fund Direct-idcw?
- 3 Years CAGR: 22.99%
- 5 Years CAGR: 15.08%
- Since Inception: 13.81%
What is the portfolio composition of Tata India Pharma & Healthcare Fund Direct-idcw?
Equity: 97.42%, Others: 2.58%.
Who manages Tata India Pharma & Healthcare Fund Direct-idcw?
Tata India Pharma & Healthcare Fund Direct-idcw is managed by Rajat Srivastava from Tata Mutual Fund.
When was the last dividend declared by Tata India Pharma & Healthcare Fund Direct-idcw?
Latest dividend was declared on 08 May 2026 at 12.00% of face value.
What is the market-cap allocation of Tata India Pharma & Healthcare Fund Direct-idcw?
Large Cap: 24.67%, Mid Cap: 34.76%, Small Cap: 40.58%.
Which are the top companies Tata India Pharma & Healthcare Fund Direct-idcw has invested in?
- Sun Pharmaceutical Industries Ltd – 10.92% of the fund's portfolio
- Sun Pharmaceutical Industries Ltd – 9.87% of the fund's portfolio
- Sun Pharmaceutical Industries Ltd – 9.38% of the fund's portfolio
- Sun Pharmaceutical Industries Ltd – 10.03% of the fund's portfolio
- Sun Pharmaceutical Industries Ltd – 10.03% of the fund's portfolio
Which are the major sectors Tata India Pharma & Healthcare Fund Direct-idcw focuses on?
- Healthcare – 173.15% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
